Literature DB >> 3040864

Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines.

P Froese, H Lemke, J Gerdes, B Havsteen, R Schwarting, H Hansen, H Stein.   

Abstract

The Hodgkin-associated Ki-1 antigen was analyzed in different cell lines. In Hodgkin analogous L428 cells, biosynthetically labeled with radioactive amino acids, the Ki-1 antibody precipitated three glycoproteins with 90, 105, and 120 kDa, respectively. Surface-labeling revealed that the two larger components were membrane-associated forms of the Ki-1 antigen, although the 90-kDa molecule was shown in pulse-chase experiments to be the precursor of the 105- and 120-kDa forms. All three forms of the Ki-1 antigen possess a tunicamycin-sensitive 6-kDa N-linked carbohydrate moiety. O-Linked oligosaccharides could not be detected. Thus, the differences in m.w. are probably not due to glycosylation. The ionophore monensin prevented the appearance of the membrane-associated molecules, which demonstrated that they are assembled between the transcompartment of the Golgi complex and their insertion into the cell membrane. The 90-kDa precursor molecule cannot be generated by disulfide reduction from the two larger forms. After internal labeling with P-32, only the 105- and 120-kDa bands became visible, indicating that the Ki-1 molecule is phosphorylated after its processing into the two larger membrane-associated forms. Analysis of the Ki-1 antigens from other cell lines demonstrated that after external labeling of two other Hodgkin-derived cell lines, six Epstein-Barr virus lymphoblastoid cell lines and one human T leukemia virus I-positive T cell line, both the 105- and the 120-kDa membrane molecules could be detected, regardless of the presence or type of virus integrated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040864

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

3.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

Authors:  E N Tsitsikov; D A Wright; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 4.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Authors:  Zainul S Hasanali; Elliot M Epner; David J Feith; Thomas P Loughran; Clare E Sample
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

6.  CD markers in pituitary adenomas.

Authors:  W Saeger
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

7.  CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.

Authors:  U Latza; H D Foss; H Dürkop; F Eitelbach; K P Dieckmann; V Loy; M Unger; G Pizzolo; H Stein
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

8.  High expression of the CD30 molecule in human decidual cells.

Authors:  K Ito; T Watanabe; R Horie; M Shiota; S Kawamura; S Mori
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

9.  Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Jimmy Esoinoza; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Pooja Mittal; Eleazar Soto; Offer Erez; Shali Mazaki-Tovi; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-11

10.  Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Sonia S Hassan; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Shali Mazaki-Tovi; Eleazar Soto; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Jimmy Espinoza
Journal:  J Matern Fetal Neonatal Med       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.